Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
13.54
+0.85 (6.70%)
NASDAQ · Last Trade: Nov 17th, 1:26 PM EST
Detailed Quote
Previous Close
12.69
Open
12.71
Bid
13.54
Ask
13.56
Day's Range
12.61 - 13.72
52 Week Range
2.600 - 16.96
Volume
838,178
Market Cap
909.56M
PE Ratio (TTM)
-7.564
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,573,026
Chart
About Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
Amylyx Pharmaceuticals is a biotechnology company focused on the development of innovative therapeutics for neurodegenerative diseases. The company aims to address significant unmet medical needs, particularly in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, through its proprietary drug candidates that target underlying biological processes. By leveraging scientific expertise and advanced research techniques, Amylyx is committed to delivering effective treatment options that enhance the quality of life for patients affected by these challenging conditions. Read More
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the third quarter ended September 30, 2025.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the following upcoming conferences, which are being conducted in-person:
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be $175.0 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.
